{"id":"https://openalex.org/W91672499","doi":null,"title":"First-Line management of CML: a state of the art review.","display_name":"First-Line management of CML: a state of the art review.","alternate_titles":[],"publication_year":2008,"publication_date":"2008-03-01","ids":{"openalex":"https://openalex.org/W91672499","mag":"91672499","pmid":"https://pubmed.ncbi.nlm.nih.gov/18397676"},"language":"en","primary_location":{"id":"pmid:18397676","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/18397676","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of the National Comprehensive Cancer Network : JNCCN","raw_type":"Journal Article"},"parent_works":[],"lineage":["https://openalex.org/W91672499"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5035964802","display_name":"Andreas Hochhaus","orcid":"https://orcid.org/0000-0003-0626-0834","observed_orcids":["https://orcid.org/0000-0003-0626-0834"]},"institutions":[{"id":"https://openalex.org/I223822909","display_name":"Heidelberg University","ror":"https://ror.org/038t36y30","country_code":"DE","type":"education","lineage":["https://openalex.org/I223822909"]},{"id":"https://openalex.org/I4387153978","display_name":"Medizinische Fakult\u00e4t Mannheim","ror":"https://ror.org/02m1z0a87","country_code":"DE","type":"education","lineage":["https://openalex.org/I4387153978"]}],"countries":["DE"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Andreas Hochhaus","raw_affiliation_strings":["Medizinische Fakultaet Mannheim, University of Heidelberg, Heidelberg, Germany. hochhaus@uni-hd.de"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medizinische Fakultaet Mannheim, University of Heidelberg, Heidelberg, Germany. hochhaus@uni-hd.de","institution_ids":["https://openalex.org/I223822909","https://openalex.org/I4387153978"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5035964802"],"corresponding_institution_ids":["https://openalex.org/I223822909","https://openalex.org/I4387153978"],"apc_list":null,"apc_paid":null,"fwci":2.0262,"has_fulltext":false,"cited_by_count":15,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.86384004,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":87,"max":95},"biblio":{"volume":"6 Suppl 2","issue":null,"first_page":"S1","last_page":"S10"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12104","display_name":"Protein Tyrosine Phosphatases","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/chronic-myeloid-leukemia","display_name":"chronic myeloid leukemia","score":0.9950000047683716},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.8240000009536743},{"id":"https://openalex.org/keywords/imatinib","display_name":"imatinib","score":0.9990000128746033},{"id":"https://openalex.org/keywords/allogeneic-stem-cell-transplantation","display_name":"allogeneic stem cell transplantation","score":0.8970000147819519},{"id":"https://openalex.org/keywords/interferon-alpha","display_name":"interferon-alpha","score":0.9950000047683716},{"id":"https://openalex.org/keywords/bcr-abl-tyrosine-kinase-inhibitors","display_name":"BCR-ABL tyrosine kinase inhibitors","score":0.8500000238418579},{"id":"https://openalex.org/keywords/chronic-phase-cml","display_name":"chronic phase CML","score":0.7979999780654907},{"id":"https://openalex.org/keywords/cytogenetic-response","display_name":"cytogenetic response","score":0.8629999756813049},{"id":"https://openalex.org/keywords/molecular-relapse","display_name":"molecular relapse","score":0.8539999723434448},{"id":"https://openalex.org/keywords/residual-disease-monitoring","display_name":"residual disease monitoring","score":0.7160000205039978},{"id":"https://openalex.org/keywords/imatinib-intolerance","display_name":"imatinib intolerance","score":0.7059999704360962},{"id":"https://openalex.org/keywords/hydroxyurea","display_name":"hydroxyurea","score":0.7480000257492065},{"id":"https://openalex.org/keywords/cytarabine","display_name":"cytarabine","score":0.9980000257492065}],"concepts":[{"id":"https://openalex.org/C2777583451","wikidata":"https://www.wikidata.org/wiki/Q177094","display_name":"Imatinib","level":3,"score":0.9396777153015137},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9297739863395691},{"id":"https://openalex.org/C2776960273","wikidata":"https://www.wikidata.org/wiki/Q729735","display_name":"Chronic myelogenous leukemia","level":3,"score":0.7340821027755737},{"id":"https://openalex.org/C3019892230","wikidata":"https://www.wikidata.org/wiki/Q177094","display_name":"Imatinib mesylate","level":4,"score":0.5038384795188904},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.4825133979320526},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4803510904312134},{"id":"https://openalex.org/C2778041864","wikidata":"https://www.wikidata.org/wiki/Q180983","display_name":"Cytarabine","level":3,"score":0.4787687361240387},{"id":"https://openalex.org/C2909179924","wikidata":"https://www.wikidata.org/wiki/Q6046488","display_name":"Alpha interferon","level":3,"score":0.4654662609100342},{"id":"https://openalex.org/C42362537","wikidata":"https://www.wikidata.org/wiki/Q87099740","display_name":"Tyrosine kinase","level":3,"score":0.4582172930240631},{"id":"https://openalex.org/C2778820342","wikidata":"https://www.wikidata.org/wiki/Q906415","display_name":"Tyrosine-kinase inhibitor","level":3,"score":0.4538392722606659},{"id":"https://openalex.org/C2778904597","wikidata":"https://www.wikidata.org/wiki/Q1129111","display_name":"Philadelphia chromosome","level":4,"score":0.45236700773239136},{"id":"https://openalex.org/C2911091166","wikidata":"https://www.wikidata.org/wiki/Q106419912","display_name":"Transplantation","level":2,"score":0.44452497363090515},{"id":"https://openalex.org/C2779823535","wikidata":"https://www.wikidata.org/wiki/Q6865356","display_name":"Minimal residual disease","level":3,"score":0.4332062304019928},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4019743502140045},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3534824848175049},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.3298724293708801},{"id":"https://openalex.org/C2776178377","wikidata":"https://www.wikidata.org/wiki/Q188269","display_name":"Interferon","level":2,"score":0.2793123722076416},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.21946832537651062},{"id":"https://openalex.org/C138626823","wikidata":"https://www.wikidata.org/wiki/Q916504","display_name":"Chromosomal translocation","level":3,"score":0.08993571996688843},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.0},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.0},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000068877","descriptor_name":"Imatinib Mesylate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001549","descriptor_name":"Benzamides","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D011505","descriptor_name":"Protein-Tyrosine Kinases","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D014184","descriptor_name":"Transplantation, Homologous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015464","descriptor_name":"Leukemia, Myelogenous, Chronic, BCR-ABL Positive","qualifier_ui":"Q000628","qualifier_name":"therapy","is_major_topic":true},{"descriptor_ui":"D016044","descriptor_name":"Fusion Proteins, bcr-abl","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016898","descriptor_name":"Interferon-alpha","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D018380","descriptor_name":"Hematopoietic Stem Cell Transplantation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true}],"locations_count":1,"locations":[{"id":"pmid:18397676","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/18397676","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of the National Comprehensive Cancer Network : JNCCN","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9537000060081482}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2282402532","https://openalex.org/W2169593238","https://openalex.org/W2029695549","https://openalex.org/W1569913789","https://openalex.org/W4231563987","https://openalex.org/W2166641737","https://openalex.org/W2092972694","https://openalex.org/W1995593356","https://openalex.org/W2170355664","https://openalex.org/W2145721329"],"abstract_inverted_index":{"With":[0],"the":[1,8,17,35,47,136,141,157,167,182],"advent":[2],"of":[3,7,22,34,37,75,135,159,170,186],"imatinib,":[4,38,172],"an":[5,51],"inhibitor":[6],"fusion":[9],"Bcl-Abl":[10],"tyrosine":[11],"kinase":[12],"that":[13,53,120],"is":[14,54,84,105,126],"responsible":[15],"for":[16,57,66,147],"disease":[18,149],"phenotype,":[19],"first-line":[20,48],"treatment":[21,68,104,154],"chronic":[23],"myelogenous":[24],"leukemia":[25],"(CML)":[26],"has":[27,44,71],"undergone":[28],"rapid":[29],"changes.":[30],"As":[31],"a":[32],"consequence":[33],"success":[36],"allogeneic":[39],"stem":[40],"cell":[41],"transplantation":[42],"(allo-SCT)":[43],"moved":[45],"from":[46],"indication":[49],"to":[50,62,107,131,143],"option":[52],"usually":[55],"considered":[56],"patients":[58,89,146],"without":[59,80],"optimal":[60],"response":[61],"imatinib":[63,70,100,116,160],"or":[64,79,82,110,162],"those":[65],"whom":[67],"with":[69,78,90,115],"failed.":[72],"First-line":[73],"use":[74],"interferon-alpha":[76],"(IFN-alpha),":[77],"cytarabine":[81],"hydroxyurea,":[83],"now":[85],"rarely":[86],"considered.":[87],"Most":[88],"newly":[91,177],"diagnosed":[92,178],"chronic-phase":[93,179],"CML":[94],"experience":[95],"complete":[96],"cytogenetic":[97,109],"responses":[98,125],"during":[99],"treatment,":[101],"but":[102],"continued":[103],"necessary":[106],"prevent":[108],"molecular":[111],"relapse.":[112],"Cumulative":[113],"evidence":[114],"and":[117,123,150,173,184,190],"IFN-alpha":[118,174],"show":[119],"experiencing":[121],"early":[122],"deep":[124],"important":[127],"in":[128,156,175],"preventing":[129],"progression":[130],"more":[132],"advanced":[133],"phases":[134],"disease.":[137],"These":[138],"features":[139],"emphasize":[140],"need":[142],"carefully":[144],"monitor":[145],"residual":[148],"provide":[151],"guidance":[152],"on":[153],"options":[155],"event":[158],"intolerance":[161],"failure.":[163],"This":[164],"article":[165],"reviews":[166],"current":[168],"role":[169],"allo-SCT,":[171],"treating":[176],"CML,":[180],"highlighting":[181],"benefits":[183],"challenges":[185],"long-term":[187],"patient":[188],"management,":[189],"discusses":[191],"emerging":[192],"trends.":[193]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W91672499","counts_by_year":[{"year":2015,"cited_by_count":1},{"year":2012,"cited_by_count":2}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
